SEC EDGARAUG 191 min read$INSM

SHAROKY MELVIN MD sold $638K of INSM (indirect holdings)

SHAROKY MELVIN MD sold 5,000 indirectly-held shares of INSMED Inc (INSM) at $127.53 ($0.64M total) on 2026-08-17.

Original reporting

SEC EDGAR · SHAROKY MELVIN MD

Published Aug 19, 2026, 8:10 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 19, 2026, 8:16 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

While the transaction is new, its modest size limits market impact.

Market read

The filing is a primary source but offers limited trading relevance due to its small scale.

What to watch

Potential upcoming financing needs or personal tax considerations for the director.

Relevance 5/10Novelty 6/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

Director Sharoky Melvin sold 5,000 shares for $637,650, reducing holdings to zero.

Expected impact

Potential slight downward pressure on INSM price.

Evidence & confidence

Sale size is under $1M and represents a complete exit by a director; market may view it as a minor negative cue.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity in micro‑caps.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

Company
INSMED Inc
Issuer of the insider transaction.
Individual
Sharoky Melvin MD
Director of INSMED Inc who sold shares.

Read at source ← All news

OCT 22

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min

OCT 20

$INSMLow

Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

citybiz.co2 min

OCT 19

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min

OCT 19

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min

OCT 15

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min

OCT 14